Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
$7.58 → $7.54 · observed estimates
Cabot Corp (CBT)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-11-04
$72.97-2.84%
Close 2026-11-05 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
7.58 → 7.54 EPS · FY ending Sep 30, 2028 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CBT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain $1.3 billion unsecured revolving credit agreement | A supporting condition in Cabot Corp's published investment case. The stated target is maintain $1.3 billion credit facility. | Intact | credit facility reduced below $1 billion | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
$7.58 → $7.54 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CBT is an industrial materials company with a growth-and-efficiency thesis, not a clear turnaround or high-growth story. The thesis is intact, and the latest signal improved, but progress across management priorities remains mixed.
The evidence describes CBT as cheap versus peers, while its overall priced-in assessment is justified and fragility is low. Expectations are not clearly stretched; the valuation model also shows a modest negative expectations gap, though confidence in that estimate is high.
Near term, fiscal 2026 guidance has been tightened, and quarterly adjusted earnings per share have shown progress with some volatility. Battery Materials growth and planned manufacturing savings support the multi-year case, but declining Reinforcement Materials earnings and recent CEO transitions leave execution uncertain.
The main company-specific swing factor is whether CBT delivers its revised fiscal 2026 earnings guidance without reversing it, which could damage management credibility. Over the multi-year view, Battery Materials growth and cost savings need to offset weakness elsewhere; sector momentum also depends on whether major materials peers continue to report strong results and guidance.
The 1-to-3-year thesis remains intact, but it depends on steady delivery from Battery Materials and cost actions amid mixed execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company keeps cash flow strong around $77M per quarter. |
| Under Pressure |
| cash flow falls below $70M per quarter |
Cash from operations: $75M FY2026-Q3; GAAP. Published target: >=77 USD_MILLIONS per quarter. Target period is not explicitly aligned with this observation. Aug 4, 202675,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
EPS near $6.25 in Q3 2026 | EPS is guided near $6.25 in Q3 2026. | Under Pressure | EPS falls below $6.0 next quarter | Diluted EPS: $0.12 per share FY2026-Q3; GAAP. Published target: 6.25 USD_PER_SHARE. Target period ends 2026-09-30; this observation covers 2026-Q3. Aug 4, 20260.12 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income near $129M per quarter | The company keeps cash flow strong around $77M per quarter. | Intact | operating income falls below $120M per quarter | Operating income: $98M FY2026-Q3; GAAP. Published target: >=129 USD_MILLIONS per quarter. Target period is not explicitly aligned with this observation. Aug 4, 202698,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$3.92B → $3.97B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $7.58 | $3,923,229,898 | 2 / 5 |
| 2026-10-02 | $7.58 | $3,923,229,898 | 2 / 5 |
| 2026-10-03 | $7.58 | $3,923,229,898 | 2 / 5 |
| 2026-10-04 | $7.58 | $3,923,229,898 | 2 / 5 |
| 2026-10-05 | $7.58 | $3,923,229,898 | 2 / 5 |
| 2026-10-06 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-07 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-08 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-09 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-10 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-11 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-12 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-13 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-14 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-15 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-16 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-17 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-18 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-19 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-20 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-21 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-22 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-23 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-24 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-25 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-26 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-27 | $7.59 | $3,938,934,629 | 2 / 5 |
| 2026-10-28 | $7.63 | $3,938,934,629 | 2 / 5 |
| 2026-10-29 | $7.63 | $3,938,934,629 | 2 / 5 |
| 2026-10-30 | $7.63 | $3,938,934,629 | 2 / 5 |
| 2026-10-31 | $7.63 | $3,938,934,629 | 2 / 5 |
| 2026-11-01 | $7.63 | $3,938,934,629 | 2 / 5 |
| 2026-11-02 | $7.63 | $3,938,934,629 | 2 / 5 |
| 2026-11-03 | $7.54 | $3,962,734,629 | 5 / 5 |
| 2026-11-04 | $7.54 | $3,972,349,883 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 3 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.